Emergent Biosolutions Inc. · NYSE:EBS
Emergent Biosolutions — 39th Annual J.P. Morgan Healthcare Conference 2021
26 slides from Emergent Biosolutions's conference presentation, Jan 11, 2021
Slide 1: Emergent BioSolutions Corporate Update
Emergent BioSolutions Corporate Update 39th Annual J.P. Morgan Healthcare Conference Robert G. Kramer President and Chief Executive Officer January 11, 2021
Slide 2: Safe Harbor Statement / Trademarks
2 2021 JP MORGAN HEALTHCARE CONFERENCE SAFE HARBOR STATEMENT / TRADEMARKS This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, our fin
Slide 3: Non-GAAP Financial Measures
3 NON-GAAP FINANCIAL MEASURES This presentation contains two financial measures (Adjusted EBITDA (Earnings Before Depreciation and Amortization, Interest and Taxes) and Adjusted EBITDA Margin) that are considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules
Slide 4: A life sciences company focused on addressing public health threats
4 A life sciences company with a diversified portfolio of products + pipeline plus CDMO services focused on addressing public health threats. WHO WE ARE • Proven 22-year track record in preparedness and response • Leadership positions in key public health threat markets • Trusted partner to governme
Slide 5: Who We Are: our four business units
5 WHO WE ARE VACCINES THERAPEUTICS DEVICES • Multiple products against significant public health threats • Robust pipeline using multiple proprietary technology modalities • Excellence in manufacturing of complex biologics • Trusted partner in rapid and on-going response to public health emergencies
Slide 6: What We Do: business units address a >$50B global market
6 WHAT WE DO Microbial BIOLOGICS TECHNOLOGY PLATFORMS PRODUCTS + PIPELINE CDMO SERVICES Our business units address a >$50B global market CBRNE Emerging Infectious Diseases Travel Health Emerging Health Crises Acute/ Emergency Care PUBLIC HEALTH THREATS 2021 JP MORGAN HEALTHCARE CONFERENCE 1. Company
Slide 7: The public health threat market landscape
7 WHAT WE DO The public health threat market landscape CBRNE Emerging Infectious Diseases Travel Health Emerging Health Crises Acute/ Emergency Care PUBLIC HEALTH THREATS CHEMICAL: Nerve agents, cyanide, chlorine, toxic industrial chemicals BIOLOGICAL: Anthrax, smallpox, botulism, Ebola, other categ
Slide 8: Diverse portfolio of products addressing multiple public health threats
8 Diverse portfolio of products1 addressing multiple public health threats PRODUCTS + PIPELINE VACCINES (injectable, oral) THERAPEUTICS (hyperimmune/mAb) DRUG-DEVICE COMBINATIONS (device, drug-device combination product) TRAVEL HEALTH Vaxchora® (Cholera Vaccine, Live, Oral) Vivotif® (Typhoid Vaccine
Slide 9: Select R&D pipeline programs
9 Select R&D pipeline programs – sources of potential future growth PRODUCTS + PIPELINE BUSINESS UNIT CANDIDATE THREAT CURRENT PHASE VACCINES AV79091 [Anthrax Vaccine Adsorbed (AVA), adjuvanted] CBRNE • Phase III; BLA filing anticipated 2021 CHIKV VLP (Chikungunya virus VLP vaccine) Travel Health/EI
Slide 10: CDMO Services: diversification and growth opportunities
10 CDMO SERVICES Biologics-focused CDMO services add diversification and growth opportunities DEVELOPMENT SERVICES (DVS) DRUG SUBSTANCE (DS) DRUG PRODUCT / PACKAGING (DP) SERVICE PILLARS 4Q2020 New Contracted Value1 ~$685M~$55M 1. Represents the new contracted value secured which we expect to realiz
Slide 11: CDMO Services: site network and related capabilities
11 CDMO SERVICES Site network and related capabilities SITE TECHNOLOGIES SERVICE PILLARS CIADM1 REVENUE GENERATING DVS DS DP 2020 2024F Baltimore, MD (Bayview) Mammalian, Viral, Microbial Baltimore, MD (Camden) Mammalian, Microbial Lansing, MI Microbial Winnipeg, Manitoba, Canada Plasma, Mammalian,
Slide 12: Financial Results: diversified revenue growth and sustained profitability
FINANCIAL RESULTS Diversified revenue growth complemented by sustained profitability 2016 2017 2018 2019 2020E 2021F TOTAL REVENUES1,2 [$M] $144 $182 $200 $280 $635 $780 2016 2017 2018 2019 2020E 2021F ADJUSTED EBITDA1,3 & ADJUSTED EBITDA MARGIN1,3 29% 32% 26% 25% 41% 39% 12 2016-2020E CAGR 45% 2016
Slide 13: Key pillars of our Growth Strategy
13 GROW THROUGH M&A STRENGTHEN R&D PORTFOLIO BUILD SCALABLE CAPABILITIES EVOLVE CULTURE EXECUTE CORE BUSINESS GROWTH STRATEGY Key pillars of our Growth Strategy 2021 JP MORGAN HEALTHCARE CONFERENCE
Slide 14: Key Takeaways
14 KEY TAKEAWAYS 1B lives protected or enhanced by 2030 2021 JP MORGAN HEALTHCARE CONFERENCE 1. Proven partner and established leader 2. Diversified product + pipeline and services mix 3. Scalable and sustainable business model 4. Strong financial foundation 5. POISED FOR CONTINUED GROWTH AND EXPANS
Slide 15: Appendix
L—s~ emergent | We Go Appendix biosolutions:
Slide 16: Reconciliation of net income to adjusted EBITDA
16 APPENDIX Reconciliation of net income to adjusted EBITDA 2021F and 2020E – 2016. 2021 JP MORGAN HEALTHCARE CONFERENCE Full Year Forecast 2021F 2020E 2019 2018 2017 2016 Net Income $420.0 - $470.0 $295.0 - $310.0 $54.5 $62.7 $82.6 $62.5 Adjustments: + Depreciation & amortization 133.0 115.0 110.7
Slide 17: Glossary of terms (1 of 2)
17 APPENDIX Glossary of terms (1 of 2) 2021 JP MORGAN HEALTHCARE CONFERENCE Term Definition ANVISA National Health Surveillance Agency Brazil BARDA Biomedical Advanced Research and Development Authority BMGS Federal Ministry of Health Germany BSL3 A biosafety level of biocontainment precautions requ
Slide 18: Glossary of terms (2 of 2)
18 APPENDIX Glossary of terms (2 of 2) 2021 JP MORGAN HEALTHCARE CONFERENCE Term Definition EMA European Medicines Agency EUA Emergency Use Authorization FDA U.S. Food and Drug Administration GAAP U.S. Generally Accepted Accounting Principles HHS U.S. Department of Health and Human Services M&A Merg
Slide 19: Our track record of key M&A since 2013
19 APPENDIX Our track record of key M&A since 2013 2021 JP MORGAN HEALTHCARE CONFERENCE 2013 Hattiesburg, MS Baltimore, MD (Camden) Winnipeg, Canada 2014 2015 Auto-injector platform 2018 Bern, Switzerland 2017 Rockville, MD Canton, MA raxibacumab injection A fully human monoclonal antibody Combined
Slide 20: The growth of CDMO at Emergent
20 APPENDIX The growth of CDMO at Emergent 2021 JP MORGAN HEALTHCARE CONFERENCE 2020E20192018201720162015201420131998 2003 SITES CDMO REVENUES $43M $49M $69M $99M $80M $460M 1$31M Internal-focused manufacturing Launch of CDMO commercialization strategy 2009 2012 1. 2020E reflects the midpoint of a g
Slide 21: Our CDMO holds a unique position in the landscape
21 APPENDIX Our CDMO holds a unique position in the landscape Emergent combines the best of both worlds: the customer focus and capacity of a pure play CDMO, plus all the expertise and experience of a successful innovator. We have the technology and facilities to bring products all the way from conc
Slide 22: Our CDMO capabilities at a glance
22 APPENDIX Our CDMO capabilities at a glance MOLECULE-TO-MARKET SERVICE OFFERINGS TECHNOLOGY PLATFORMS DEVELOPMENT AND MANUFACTURING SITES3 5 9 2021 JP MORGAN HEALTHCARE CONFERENCE
Slide 23: Our CDMO offers end-to-end integrated services
23 APPENDIX Our CDMO offers end-to-end integrated services DEVELOPMENT SERVICES (DVS) DRUG SUBSTANCE MANUFACTURING (DS) DRUG PRODUCT MANUFACTURING AND PACKAGING (DP) 2021 JP MORGAN HEALTHCARE CONFERENCE
Slide 24: CDMO business utilizes multiple platform technologies
24 APPENDIX Our CDMO business utilizes multiple platform technologies addressing compelling market opportunities ▪ Molecule-to-market development and manufacturing services with successful track record of innovation. ▪ Enterprise team of more than 1400 technical and quality compliance professionals.
Slide 25: CDMO key growth initiatives
25 APPENDIX CDMO key growth initiatives 2021 JP MORGAN HEALTHCARE CONFERENCE INVEST TO MEET MARKET NEEDS DRIVE GLOBAL BRAND AWARENESS EXPAND SALES AND BUSINESS DEVELOPMENT TEAMS ENHANCE MOLECULE- TO-MARKET OFFERING EXPLORE PARTNERSHIP OPPORTUNITIES BALANCE CLINICAL WITH COMMERCIAL CROSS-SELL TO EXIS
Slide 26: www.emergentbiosolutions.com
www.emergentbiosolutions.com
Emergent BioSolutions — 39th Annual J.P. Morgan Healthcare Conference 2021 on 6ix